The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Treatment options for patients with LBCL who relapse or are refractory to initial treatment
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses treatment options for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). For patients with primary refractory disease, CAR-T therapy is often recommended, but if it fails, chemotherapy with bendamustine and polatuzumab may be more effective than bispecific antibodies. Patients who relapse after initially responding to CAR-T might benefit from CD20/CD3 bispecifics. If these are ineffective, alternatives include loncastuximab tesirine, the combination of rituximab, polatuzumab, and bendamustine, or lenalidomide with tafasitamab. The ECHELON-3 trial (NCT04404283) also highlights brentuximab vedotin plus lenalidomide and rituximab as an option. More treatment options are available for those who relapse after a year. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
